Smoflipid and Complement factor c3 decreased - a phase IV clinical study of FDA data

Summary:

Complement factor c3 decreased is found among people who take Smoflipid, especially for people who are female, 0-1 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Smoflipid and have Complement factor c3 decreased. It is created by eHealthMe based on reports of 497 people who have side effects when taking Smoflipid from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 26, 2023

497 people reported to have side effects when taking Smoflipid.
Among them, 8 people (1.61%) have Complement factor c3 decreased.

What is Smoflipid?

Smoflipid has active ingredients of lipid injectable emulsion (soybean;mct;olive;fish). eHealthMe is studying from 498 Smoflipid users for its effectiveness, alternative drugs and more.

What is Complement factor c3 decreased?

Complement factor c3 decreased is found to be associated with 227 drugs and 170 conditions by eHealthMe.

Number of Smoflipid and Complement factor c3 decreased reports submitted per year:

Could Smoflipid cause Complement factor c3 decreased?

Time on Smoflipid when people have Complement factor c3 decreased *:

Gender of people who have Complement factor c3 decreased when taking Smoflipid *:

female: 100 %
male: 0.0 %

Age of people who have Complement factor c3 decreased when taking Smoflipid *:

Common drugs people take besides Smoflipid *:

Common side effects people have besides Complement factor c3 decreased *:

Urinary Tract Infection: 8 people, 100.00%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 8 people, 100.00%
Hypertensive Crisis: 8 people, 100.00%
Hyperkalemia (damage to or disease of the kidney): 8 people, 100.00%
High Blood Pressure: 8 people, 100.00%
Haemolytic Anaemia (anaemia due to haemolysis): 8 people, 100.00%
Haemoglobin Decreased: 8 people, 100.00%
Haematuria (presence of blood in urine): 8 people, 100.00%
Fever: 8 people, 100.00%
Escherichia Urinary Tract Infection (urinary tract infection by escherichia coli): 8 people, 100.00%

Common conditions people have *:

Spinal Muscular Atrophy (wasting of spinal muscles): 8 people, 100.00%
Fluid Overload (too much fluid in the blood): 8 people, 100.00%
Fatty Acid Deficiency: 8 people, 100.00%
Dry Skin: 8 people, 100.00%
Constipation: 8 people, 100.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 4 people, 50.00%
Gastric Disorder (disease of stomach): 3 people, 37.50%

* Approximation only. Some reports may have incomplete information.

Do you take Smoflipid and have Complement factor c3 decreased?

Check whether Complement factor c3 decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Complement factor c3 decreased and when was it recovered:

Complement factor c3 decreased in Smoflipid

Expand to all the drugs that have ingredients of lipid injectable emulsion (soybean;mct;olive;fish):

Complement factor c3 decreased and drugs with ingredients of lipid injectable emulsion (soybean;mct;olive;fish)

Alternative drugs to, pros and cons of Smoflipid:

Smoflipid (498 reports)

Complement factor c3 decreased treatments and more:

Complement factor c3 decreased (289 reports)

COVID vaccines that are related to Complement factor c3 decreased:

All the drugs that are associated with Complement factor c3 decreased:

Complement factor c3 decreased (227 drugs)

All the conditions that are associated with Complement factor c3 decreased:

Complement factor c3 decreased (170 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lipid injectable emulsion (soybean;mct;olive;fish) (the active ingredients of Smoflipid) and Smoflipid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.